ICD-10 D63.0 is officially defined as "Anemia in neoplastic disease." code D63.0 is referenced in 9 tracked payer policy changes from Independence Blue Cross, Aetna, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D63.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Independence Blue Cross updated MA08.011i to align with FDA labeling and NCCN guidelines for Erythropoiesis Stimulating Agents (ESAs). The policy revises medical necessity criteria for myelodysplastic syndrome, cancer-related anemia, HIV/AIDS, and pediatric chronic kidney disease, and adds 18 new ICD-10 diagnosis codes effective June 29, 2026.
Independence Blue Cross Medicare Advantage policy MA08.150b (effective 03/23/2026) supersedes MA08.150a with new coverage criteria for IV iron in pediatric patients and expanded ICD-10 diagnosis codes including pregnancy-related anemia (O99.011-O99.013, O99.019, O99.02, O99.03) and chemotherapy-induced anemia (D64.81). The policy maintains preferred vs. nonpreferred product tiering for adults 18+ and excludes preferred product requirements for patients under 18 and pregnant individuals.
Independence Blue Cross updated MA08.150a to MA08.150b, adding new coverage criteria for pediatric IV iron use and expanding ICD-10 diagnosis codes to include pregnancy-related anemias (O99.011-O99.019, O99.02, O99.03) and chemotherapy-induced anemia (D64.81). The policy maintains preferred vs. nonpreferred product designations with specific coverage rules based on prior treatment history and contraindication documentation.
Independence Blue Cross updated policy 08.02.29a to 08.02.29b, adding new coverage criteria for pediatric IV iron preparations, expanding ICD-10 diagnosis codes to include pregnancy-related anemia and heart failure conditions, and clarifying preferred vs. nonpreferred product designations. Billing teams must implement these expanded diagnosis codes and ensure claims reflect the new clinical criteria effective March 23, 2026.
Independence Blue Cross updated IV Iron Preparations policy (08.02.29b, effective 03/23/2026) to add new coverage criteria for pediatric patients and expand ICD-10 diagnosis codes to include pregnancy-related anemias, anemia in neoplastic disease, chemotherapy-induced anemia, and heart failure. The preferred product hierarchy remains unchanged for adults, but new clinical scenarios now have defined coverage pathways.
Independence Blue Cross updated ESA policy 08.00.75q to 08.00.75r effective 11/17/2025, revising coverage criteria for Myelodysplastic Syndrome and Cancer-Related Anemia based on FDA labeling and NCCN guidelines. Seven new ICD-10 diagnosis codes were added to expand eligible patient populations, including acute panmyelosis with myelofibrosis variants, myelodysplastic disease, chronic myeloproliferative disease, osteomyelofibrosis, and anemia in neoplastic disease.
Feraheme, Ferrlecit, Injectafer, Monoferric and Venofer are medically necessary only for commercial members who have a contraindication, intolerance or ineffective response to the lower cost alternatives generic ferumoxytol, generic iron sucrose, generic sodium ferric gluconate and INFeD (iron dextran) for the labeled indication. Precertification is required for Feraheme, Ferrlecit, generic sodium ferric gluconate, Injectafer, Monoferric, Venofer and generic iron sucrose in applicable plan designs. Intravenous iron is considered experimental, investigational or unproven for other indications, including acute mountain sickness and anemia of inflammation, and it is contraindicated for genetic hemochromatosis or hemochromatosis secondary to iron overload.
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan expanded ClaimsXten, their claims auditing tool that checks coding against NCCI edits, to a third phase effective March 2026. Phase 3 adds review rules for outpatient consultation coding, duplicate claim submissions by facilities, and unbundled code pairs. ClaimsXten edits appear on remittance advice and do not stop claims from entering the payer's claim system.
Epogen (epoetin alfa), Procrit (epoetin alfa), and Retacrit (epoetin alfa-epbx) are considered medically necessary for anemia related to zidovudine therapy in HIV-infected individuals, anemia in non-myeloid malignancies caused by concomitantly administered chemotherapy, anemia in individuals scheduled for elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions, and anemia associated with chronic kidney disease. Aranesp (darbepoetin alfa) is considered medically necessary for anemia associated with chronic kidney disease, including individuals on dialysis and not on dialysis, and for anemia in non-myeloid malignancies caused by concomitantly administered chemotherapy. The 09/09/2025 revision updated the indications descriptions and added that services related to delivery or administration of a medication determined to be not medically necessary are also considered not medically necessary.
Watch D63.0
Get one email when a payer policy names D63.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.